LGVN Longeveron Inc - Ordinary Shares - Class A

$LGVN Well I was right about 1 thing. They were not gonna go to the conference with bad data.

$LGVN Started a starter position here at 2.75/share. Bought 1/3 my total will add 2/3 more if it drops and averages down. -3.2m shares OS -Laromestrocel had bad data in HLHS but still has promise in Age related Fraility, Pediatric Cardiomyapothy, and Alzheimer's. Likely still value in the drug. -NASDAQ shell has value of 5-7m or approx. ~1.50-2.00/share -Net cash likely close to zero Value based on NASDAQ shell alone + any value of drug. Seems to be at a good buying spot for a starter position. Running out of cash and announced strat alts means they are either going to raise cash through PIPE to fund future trials, RM, partner, or sell the asset completely. All scenarios have limited downside imo. -30% downside risk for 100-200%+ upside potential imo at current levels of 2.75/share.

$LGVN Getting use out of that block button this morning 🙃 Take the cross posting and drive by DD elsewhere. Most of us are well aware this is a make or break type of play. Their financial situation is precarious but if the data is good it is a billion + TAM high unmet need. They are actively seeking non-dilutive capital via partnership. They could very well be working on that now with the data unblinded (nobody knows).

$LGVN They present at HC Wainwright every year so can't take too much from that but interesting to note in terms of of PR timing, with the phase 1 results there is a weird similarly with current period. They did a data cut off 31st Aug 2021, then did the phase 1 topline results Thurs Sept 9th, then presented at HC Wainwright Mon Sep 13th. So they seemed to like having the data out a bit before the conference. Monday pre market is still most likely for phase 2b I would say (assuming they are planned to have them before conference) but this makes me think the results could also be tomo or Fri if ready. Obv these phase2b results would be harder to do quickly compared to the phase 1 however so may not be ready.

$LGVN Here is a relevant example for $LGVN investors: the FDA’s approval of FAYUVI for an ultra-rare pediatric disease shows that rare-disease programs can receive regulatory flexibility when large conventional trials are difficult, provided the overall evidence is convincing. For $LGVN, ELPIS II missed its primary RVEF endpoint, but the FDA had already indicated that RVEF was not the most appropriate efficacy endpoint and highlighted outcomes such as MACE, mortality, transplantation, and transplant-free survival. This does not guarantee approval, but it also means the HLHS program should not be declared dead before the FDA reviews the complete dataset. And remember, $LGVN’s value extends beyond HLHS, with programs in Alzheimer’s, Aging-related Frailty, and Pediatric DCM.

$LGVN Started a small position here. (11.3M Current assets - 5M Total Liabilities - 6M Cash burn + 7.5M Nasdaq Shell) / 3.2M Shares outstanding = ~$2.40 PPS. Seems like there is limited downside from here IMO.

$LGVN Knew it was boom or bust. That's why it was only side money. Better luck next time.

$LGVN The reverse merger valuation theory..... Recent reverse merger transacations of various companies below and the value given to their shells (net of cash). The median shell valuation was around 10m. If LGVN gets 10m valuation for shell and has net cash of (-5m) at closing, valuation of shell will be 5m / 3.2 OS = 1.6/share FLOOR for shell only . Add in value of laromestrocel at 5m conservative and you get back to 10m / 3.2m or 3.2/share. So downside risk from these levels of ~30% and upside potential of whatever drug is worth. I'm a continuous buyer at these levels.

$LGVN Don’t judge $LGVN solely by the ELPIS II results! Its Laromestrocel therapy for age-related frailty improved 6-minute walking distance by 63.4 meters versus placebo (p=0.0077) in a clinical trial involving 148 participants. $LGVN was among 10 teams awarded $1M in the XPRIZE Healthspan competition, selected from over 600 applicants. It has advanced to compete for prizes totaling up to $81M—a strong endorsement of its frailty program’s potential, though broader efficacy remains to be proven.

$LGVN Successfully averaged down. Now at 60k shares @ 2.55/share. Summary below still stands.

$LGVN It is too early to declare Laromestrocel a failed therapy. ELPIS II missed the RVEF primary endpoint, but the FDA had already indicated that RVEF was not an appropriate measure of efficacy and highlighted outcomes such as MACE, mortality, and transplant-free survival. MACE was numerically reduced by about 31% (12 vs. 19 events), although not statistically significant. With only 40 patients and HLHS being an extremely rare disease, the small sample size matters, and the FDA allows regulatory flexibility in rare-disease development. The full detailed data — and ultimately the FDA’s assessment — will be critical in determining whether the therapy truly failed or still shows meaningful clinical benefit.

$LGVN who ever bailed just before the market closed should be investigated! That volume spike wasn’t luck!

$LGVN In terms of the phase 1 when you add the 4 'run ins' patients who were also given the drug initially for safety but they took their data too up to year 1 to the 10n there was 14 out of 14 survived and were transplant free in first year. It seems there is around 15% chance of dying or needing heart transplant in first year so chance of 14 out of 14 is around 10% by chance. 10% is certainly still possible of course but is intriguing ahead of phase 2b. Even more interesting none of the 14 had any MACE events. There is around 17% chance of a MACE event so 14/14 with no MACE is around 7.4% by chance.

$LGVN RS killed the momentum we had when we were moving to .90+. Drifting in the wind until data. Targeting $18-20

$LGVN ...Should gradually see this go down to $1.50 or so which would be around .15 cents pre split, no revenue stream coming in just kills these speculative stocks...not sure what their plan is moving forward but hoping they can give an update soon.

$LGVN Dumped it at opening, should have seen it coming when they were a no show at conference. Lesson learned.

$LGVN so we got unexpected outcome today with the Phase 2b results for (HLHS) treatment. (Negative) But on Feb we got that laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months (positive)

$LGVN The screenshot describes Wainwright as providing investment banking, corporate finance, and strategic advisory services to growth companies. And in LGVN's case, we already know Wainwright acted as the exclusive placement agent for that up-to-$30M private placement. So the relationship potentially includes: LGVN ↔ Wainwright ↔ institutional investors / financing / strategic advisory That's why Monday is more puzzling than if LGVN simply missed a random industry conference. Wainwright is a firm with which LGVN recently had a significant financial relationship...........

$LGVN For what it's worth I asked in the technical support chat for HC Wainwright if the event actually occurred yesterday and they confirmed it did not. I asked if they could give me any indication why and they said sorry it was technical support chat only. Don't suppose anyone might have phoned the IR for any more info on this? I would myself but am in UK and it gives a toll free number that only works in USA I believe.

$LGVN reading on turstocktalks that news is extremely positive. Hope they know what they are talking about. Wonder if something leaked ?